Big news for global health! The World Health Organization (WHO) just approved the MVA-BN vaccine—the first-ever mpox vaccine to join its prequalification list. Developed by Bavarian Nordic A/S, this two-dose jab could be a game-changer for regions battling outbreaks, especially in Africa. 💪
WHO Director-General Tedros Adhanom Ghebreyesus called the move a “critical step” to curb transmission and protect vulnerable communities. “Equitable access is key,” he stressed, urging faster vaccine distribution to high-risk areas.
Here’s the rundown: The vaccine is 76% effective after one dose and jumps to 82% after the second shot (given four weeks apart). While data collection continues, WHO Assistant Director-General Yukiko Nakatani says prequalification will “speed up approvals” worldwide, helping agencies like UNICEF snap up doses faster. 🚀
Mpox cases have surged globally since 2022, but this approval brings hope for a safer future. Think fewer outbreaks, more Netflix-and-chill vibes. 📉🍿
